Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME(®) trial

AIMS: We previously reported that in the EMPA-REG OUTCOME(®) trial, empagliflozin added to standard of care reduced the risk of 3-point major adverse cardiovascular events, cardiovascular and all-cause death, and hospitalization for heart failure in patients with type 2 diabetes and high cardiovascu...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Eur Heart J
Hlavní autoři: Fitchett, David, Zinman, Bernard, Wanner, Christoph, Lachin, John M., Hantel, Stefan, Salsali, Afshin, Johansen, Odd Erik, Woerle, Hans J., Broedl, Uli C., Inzucchi, Silvio E.
Médium: Artigo
Jazyk:Inglês
Vydáno: Oxford University Press 2016
Témata:
Aha Fasttrack
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4872285/
https://ncbi.nlm.nih.gov/pubmed/26819227
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/eurheartj/ehv728
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky